Blog

TAMPA, FL / ACCESS Newswire / May 19, 2025 / As artificial intelligence (AI) transforms healthcare, organizations face unprecedented opportunities-and risks. From clinical decision support to patient engagement, AI-enabled technologies promise efficiency and innovation. However, without robust governance, risk management, and compliance (GRC) frameworks, these advancements can lead to ethical dilemmas, regulatory violations, and patient harm. Newton3, a Tampa-based strategic advisory firm, specializes in helping healthcare leaders navigate this complex landscape, ensuring AI deployments are both impactful and accountable.

The Risks of Unregulated AI in Healthcare
AI applications in healthcare, such as natural language processing for clinical transcription or machine learning for disease diagnosis, carry inherent risks:

• Bias and Inequity: AI models trained on biased datasets can perpetuate disparities in care.

• Regulatory Non-Compliance: HIPAA, GDPR, and emerging AI-specific regulations require rigorous adherence.

• Lack of Transparency: “Black box” algorithms undermine trust in AI-driven decisions.

Without GRC programs, healthcare organizations risk financial penalties, reputational damage, patient safety breaches, and, most critically, potential patient harm.

The NIST AI Risk Management Framework: A Roadmap for Healthcare
The National Institute of Standards and Technology (NIST) AI Risk Management Framework (RMF) 1.0 and NIST AI 600-1, provide a structured approach to mitigate these risks for both Narrow and General AI. Key steps include:

• Governance: Establish clear accountability for AI systems, including oversight committees and ethical guidelines.

• Risk Assessment: Identify and prioritize risks specific to AI use cases (e.g., diagnostic errors in image analysis).

• Compliance Integration: Align AI deployments with existing healthcare regulations and future-proof for evolving standards.

Newton3’s GRC NIST Certification Toolkit helps organizations implement this framework, ensuring AI systems are transparent, explainable (XAI), and auditable.

Newton3’s Role in Shaping Responsible AI

Newton3 offers tailored solutions for healthcare leaders, including:

• AI GRC Training: Equip teams with skills to manage AI risks.

• Fractional AI Officer Services: Embed GRC expertise into organizational leadership.

• Platform-Agnostic Advisory: Support unbiased AI strategy, including integrations like Salesforce Agentforce.

Call to Action
For healthcare CEOs and CTOs, the time to act is now. Proactive GRC programs are not just a regulatory requirement-they are a competitive advantage. Contact Newton3 to build a governance strategy that aligns innovation with accountability.

About Newton3
Newton3 is a Tampa-based strategic advisory firm specializing in AI governance, risk management, and compliance (GRC) within the healthcare sector. The company empowers organizations to maximize the value of their AI investments across platforms like AWS, Google Cloud, Azure, ServiceNow’s NOW Platform AI, and Salesforce’s Agentforce AI. By embedding GRC frameworks into AI deployments, Newton3 ensures that innovations are not only effective but also ethically sound and compliant with regulatory standards.

Their services encompass predictive intelligence, virtual agents, and process optimization, providing methodologies that align AI strategies with organizational goals. Newton3’s commitment to risk-aware innovation helps clients navigate the complexities of AI integration, maintaining transparency, security, and regulatory integrity throughout the process.

Learn more at www.newton3ai.com

Disclaimer
This press release was prepared for syndication by Evrima Chicago, LLC. The views and opinions expressed herein are those of the original authors or sources and do not necessarily reflect the official position of Evrima Chicago. The Evrima editorial team has compiled and formatted this release based on publicly available or provided content. For inquiries, interview requests, or editorial verification, please contact the Evrima Chicago team at PR@EvrimaChicago.com or visit www.evrimachicago.com.

SOURCE: Newton3 AI

View the original press release on ACCESS Newswire

Strategic rollout to include televised interviews, Times Square billboards, and social media amplification

NEW YORK CITY, NEW YORK / ACCESS Newswire / May 19, 2025 / Vita Bella, the lifestyle and wellness brand behind VitaBella.com, has entered into a strategic media partnership with New to The Street, the nationally recognized financial news platform known for spotlighting innovative companies across television, digital, and outdoor media.

As part of the agreement, Vita Bella will be featured in a series of national TV interviews, Times Square billboard campaigns, and a targeted social media strategy to build visibility and drive consumer engagement.

“This partnership with New to The Street gives us a powerful platform to share our mission of delivering customized, clinical grade care with modern convenience,” said Phil Vella, Founder of Vita Bella. “We’re excited to step into the national spotlight at such a pivotal time in the growth of our company.”

“Vita Bella represents the kind of forward-thinking, high-integrity brand that aligns perfectly with our platform,” said Vince Caruso, Co-Founder and CEO of New to The Street. “We’re proud to help share their story with audiences worldwide through our trusted media channels, including our expanding Bloomberg coverage and our digital network of over 2.5 million subscribers.”

The campaign will air on Fox Business and Bloomberg Television (as sponsored programming), be featured on New to The Street’s YouTube channel, and supported by Times Square billboard exposure managed by Accel Media International.

About Vita Bella

Vita Bella is redefining what it means to live well – with a portfolio of premium treatments and advanced medications designed to elevate health, energy, and lifestyle. Backed by a data-driven clinical model, Vita Bella’s team of licensed physician’s crafts personalized wellness protocols tailored to each patient’s unique needs. More than a brand, Vita Bella is a movement. Through its innovative digital platform, the company delivers a one-of-a-kind blend of clinical-grade care and modern convenience – empowering individuals across the country to look, feel, and perform at their best, every single day.

About New to The Street

New to The Street is a multi-platform media brand that has featured over 600 companies across its syndicated broadcasts, including Fox Business and Bloomberg Television. With over 2.5 million YouTube subscribers, a powerful social media presence, and iconic Times Square billboard access, the platform delivers Opportunities to Consider™ to investors and consumers worldwide. Beginning in June, New to The Street expands its Bloomberg Television broadcasts into the Middle East, reaching an additional 26 million homes, further extending its international media footprint.

Media Contact:
Monica Brennan
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

AUSTIN, TEXAS / ACCESS Newswire / May 19, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) (“TRNR” or the “Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands and pending acquirer of Sportstech and Wattbike, today announced that it has updated its investor FAQ’s on its investor website in response to shareholder questions about today’s increase of 2025 pro forma revenue guidance to more than $75M as well as other questions.

For more commentary, information and details on the rationale for and structure of the expected acquisition, please see TRNR’s investor presentation on the Company’s investor website as well as its required filings with the US Securities & Exchange Commission (SEC).

TRNR Investor Contact
ir@interactivestrength.com

About Interactive Strength Inc.:

Interactive Strength Inc. produces innovative specialty fitness equipment and digital fitness services under two main brands: 1) CLMBR and 2) FORME. Interactive Strength Inc. is listed on NASDAQ (symbol:TRNR).

CLMBR is a vertical climbing machine that offers an efficient and effective full-body strength and cardio workout. CLMBR’s design is compact and easy to move – making it perfect for commercial or in-home use. With its low impact and ergonomic movement, CLMBR is safe for most ages and levels of ability and can be found at gyms and fitness studios, hotels, and physical therapy facilities, as well as available for consumers at home. www.clmbr.com.

FORME is a digital fitness platform that combines premium smart gyms with live virtual personal training and coaching to deliver an immersive experience and better outcomes for both consumers and trainers. FORME delivers an immersive and dynamic fitness experience through two connected hardware products: 1) The FORME Studio Lift (fitness mirror and cable-based digital resistance) and 2) The FORME Studio (fitness mirror). In addition to the company’s connected fitness hardware products, FORME offers expert personal training and health coaching in different formats and price points through Video On-Demand, Custom Training, and Live 1:1 virtual personal training. www.formelife.com.

Forward Looking Statements:
This press release includes certain statements that are “forward-looking statements” for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management’s assumptions, views, plans, objectives and projections about the future. Forward-looking statements generally are accompanied by words such as “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “may”, “should”, “will”, “would”, “will be”, “will continue”, “will likely result” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the possibility of acquiring future businesses or completing the referenced pending transactions in a timely manner or at all, the financial performance of those acquisitions and the resulting guidance of having more than $75m of pro forma revenue in 2025, achieving profitability by Q4, and the financial performance of the acquisition targets which have not been audited or reviewed by a PCAOB auditor and could vary materially (a) once that audit or review work is completed and such financials are included in the Company’s reported financials and (b) due to the effect of the exchange rates of foreign currencies which can be volatile. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Risks and uncertainties include but are not limited to: demand for our products; competition, including technological advances made by and new products released by our competitors; our ability to accurately forecast consumer demand for our products and adequately maintain our inventory; and our reliance on a limited number of suppliers and distributors for our products. A further list and descriptions of these risks, uncertainties and other factors can be found in filings with the Securities and Exchange Commission. To the extent permitted under applicable law, the Company assumes no obligation to update any forward-looking statements.

# # #

SOURCE: Interactive Strength Inc.

View the original press release on ACCESS Newswire

AUSTIN, TX / ACCESS Newswire / May 19, 2025 / ProScore Technologies (ProScore), an innovative and growing provider of software and services to assist companies manage, track, monitor compliance, and create efficiencies around their growing workforces, including to monitor compliance around the requirements of the Inflation Reduction Act (IRA), announced a new multi-year partnership with Moss & Associates, LLC (Moss), the number one EPC in utility-scale solar according to Solar Power World magazine, with over 20 GW of experience.

Under the terms of the agreement, ProScore will provide its proprietary software and services for Moss, its subcontractors, and its development partners on clean energy projects to monitor compliance.

ProScore is working with Moss to integrate systems and manage data from project teams, subcontractors, and suppliers. The parties foresee that the platform will be a valuable tool to assist in the management and oversight of prevailing wage and apprenticeship requirements, and other tax incentive criteria throughout the lifecycle of Moss’s solar construction projects.

“We’re thrilled to be working with Moss,” said Ron Nickelson, Founder and President of ProScore. “Early on we recognized the need for a technology-based solution that provides project level transparency in real time. This collaboration establishes a new standard for IRA reporting.”

About ProScore Technologies

ProScore is the industry standard for compliance. Powered by NVIDIA GB200 superchips, our platform delivers the industry’s lowest total operational costs, enhances data accuracy, and provides real-time reporting with unmatched speed and precision.

Discover how ProScore’s innovative platform supports EPC workflows through smart prevailing wage analysis, apprenticeship tracking, and automated compliance documentation. Visit proscore.ai/demo-quest to request your demo and see the platform in action.

Media Contact:

Seamus Tierney
VP, Marketing & Creative
marketing@proscore.ai
(737) 358-7661
ProScore.ai

SOURCE: ProScore Technologies LLC

View the original press release on ACCESS Newswire

MCLEAN, VA / ACCESS Newswire / May 19, 2025 / Gladstone Investment Corporation (Nasdaq:GAIN) (“Gladstone Investment”) is pleased to announce its acquisition of Smart Chemical Solutions, LLC (“Smart Chemical”), along with Xyresic Capital (“Xyresic”). Gladstone Investment provided equity and senior secured debt to complete the transaction.

Smart Chemical, based in Midland, Texas, is a leading provider of production chemicals for onshore oil and gas operators. “Smart Chemical is a valuable partner to major energy companies operating throughout the United States. We are very excited to partner with this talented team as it accelerates its growth strategy, expands its product portfolio and strengthens its ability to serve operators across the energy sector. Further, we are thrilled to expand our relationship with Xyresic,” said Christopher Lee, Senior Managing Director of Gladstone Investment.

“This investment represents our dedication to our ultimate goal of investing in quality companies that will produce stable income for dividends to Gladstone Investment’s shareholders, as well as longer-term capital appreciation resulting in capital gains,” said David Dullum, President of Gladstone Investment.

Gladstone Investment is a publicly traded business development company that seeks to make equity and secured debt investments in lower middle market businesses in connection with acquisitions, changes in control, and recapitalizations. Additional information on the transaction can be found at www.gladstoneinvestment.com.

For Investor Relations inquiries related to any of the monthly dividend paying Gladstone funds, please visit www.gladstone.com.

Forward-looking Statements:

The statements in this press release regarding the longer-term prospects of Gladstone Investment and Smart Chemical and its management team, and the ability of Gladstone Investment and Smart Chemical to grow and expand are “forward-looking statements.” These forward-looking statements inherently involve certain risks and uncertainties in predicting future results and conditions. Although these statements are based on Gladstone Investment’s current plans that are believed to be reasonable as of the date of this press release, a number of factors could cause actual results and conditions to differ materially from these forward-looking statements, including those factors described from time to time in Gladstone Investment’s filings with the Securities and Exchange Commission. Gladstone Investment undertakes no obligation to update or revise these forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For further information: Gladstone Investment Corporation, (703) 287-5893

SOURCE: Gladstone Investment Corporation

View the original press release on ACCESS Newswire

Groundbreaking Automation Poised to Deliver Enhanced Efficiency and Patient Care

Marks Arrive AI’s First Revenue Generating Arrive Point^TM Deployment

GREENFIELD, INDIANA / ACCESS Newswire / May 19, 2025 / Arrive AI (NASDAQ:ARAI), a pioneering autonomous delivery network anchored by patented AI-powered Arrive Points™, and Hancock Health, a regional hospital and member of the Mayo Clinic Care Network located in Greenfield, IN, today announced the launch of a two-year partnership. The agreement marks Arrive AI’s first revenue generating deployment. The collaboration will explore the transformative potential of asynchronous robotic automation for medical deliveries within hospitals, aiming to unlock significant cost savings through technological advancements and operational efficiencies using Arrive AI technology.

Operations began today with the Arrive Point, as Arrive AI’s secure and patented autonomous delivery station took center stage. This innovative device will serve as a reliable, chain-of-custody-compliant hub for the seamless drop-off and pickup of biospecimens from the cancer center.

This partnership places Hancock Health at the forefront of autonomous medical logistics, with potential applications across its broader network of more than 30 locations in East Central Indiana.

“At Hancock Health, our top priority is delivering personalized and high-quality care in the most affordable and efficient way possible,” said Steve Long, President and CEO of Hancock Health. “Embracing automation opens the door to transformative improvements – reducing costs, accelerating the delivery of critical items like test results, medications, and lab specimens, and strengthening the security and reliability of our services. Every improvement in these areas enhances the overall patient experience.”

Dan O’Toole, CEO of Arrive AI, commented, “This live deployment marks a significant milestone for Arrive AI as we move from pilot programs to generating revenue and demonstrating the real-world value of our autonomous delivery solutions. We are eager to collaborate closely with Hancock Health and validate the tangible benefits Arrive AI will bring to their operations.”

Hancock Health has identified operational inefficiencies that include having medical personnel make more than a dozen daily trips between its clinics and hospital lab to deliver specimens. Those trips pull staff from critical duties, delay lab results and increase labor costs. The multi-phase test with Arrive AI will showcase how cutting edge, asynchronous technology is set to change the healthcare landscape in a seismic way.

The phased rollout of the initiative includes: a comprehensive readiness evaluation; the installation of robotic technology at the hospital’s Sue Ann Wortman Cancer Center and laboratory; the development of optimized delivery routes; the expansion of technology deployment to off-campus locations; and the introduction of drone-based transport for time-sensitive and off-site medical deliveries. Each phase will incorporate the Arrive Point, providing a standardized and secure interface for all chain-of-custody transfers.

According to the terms of the agreement, Arrive AI anticipates leveraging the insights gained from this trial by September 2027 to develop a scalable framework for integrating ground robotics, courier networks, and drones across Hancock Health’s entire network. Arrive AI will spearhead the design, deployment, and optimization of this integrated system, ensuring regulatory compliance, operational feasibility, and a validated return on investment. Key strategies for enhancing efficiency and reliability include:

• Replacing manual specimen transport with robotic automation.

• Providing Arrive Point storage devices for round-the-clock deliveries.

• Deploying drones for urgent and off-campus transport needs.

-30-

About Arrive AI: Arrive AI’s patented last mile (ALM) platform enables drone-based and human mail delivery to and from a physical smart mailbox, while providing tracking data, smart logistics alerts, and advanced chain of custody controls to secure the last-mile delivery for all shippers, delivery services, and autonomous delivery networks. Arrive AI makes the exchange of goods between people, robots, and drones frictionless, efficient, and convenient through artificial intelligence, autonomous technology, and interoperability with smart devices including doorbells, lighting and security systems. Learn more details about the company’s patents here. See videos of the smart mailbox in action here.

About Hancock Health: Hancock Health, a Mayo Clinic Care Network Member, is a full-service healthcare network serving East Central Indiana at Hancock Regional Hospital and more than 30 other locations to ensure convenience to high quality care. A member of the Suburban Health Organization (SHO) and partner to Peyton Manning Children’s Hospital, Hancock Health believes in the power of partnerships to lower costs and improve health outcomes for patients. Hancock Health’s expert physicians have access to Mayo Clinic’s research, diagnostic, and treatment resources across specialties including cancer care, women’s health, primary care, wellness, emergency medicine, and more – all with the goal of improving health outcomes and making health possible for East Central Indiana. Media Contact: Claire Hunter: claire@pencemediagroup.com

Cautionary Note Regarding Forward Looking Statements 

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements (including statements related to the closing, and the anticipated benefits to the Company, of the private placement described herein) related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” ,”optimistic” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement for more complete information, including the risk factors that may affect future results, which are available for review at https://www.sec.gov/ Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

Media contact: Cheryl Reed, media@arriveai.com
Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

SAN BERNARDINO, CA / ACCESS Newswire / May 19, 2025 / Dateline Resources Limited (OTC:DTREF)(ASX:DTR) is pleased to update its shareholders on the strong financial position and ongoing progress of its flagship Colosseum Gold and Rare Earth Element (REE) Project in California. With a robust cash balance and recent capital inflows, the Company is fully funded to complete the Bankable Feasibility Study (BFS) for the Colosseum Gold Project, a significant milestone in unlocking the project’s value.

Key Highlights

Dateline Resources is well-positioned with current cash reserves of $1.95 million, which are expected to increase to $2.3 million upon receipt of part of the proceeds from the Udu Copper Project sale. The Company has raised approximately $1.1 million through recent warrant exercises, reflecting strong shareholder support. The BFS for the 1.1 million ounce Colosseum Gold Project is progressing on schedule, with metallurgical test work now underway. Additionally, planning for a dedicated REE drilling program at Colosseum is being advanced and guided by leading REE experts. The Company is also on track to uplist to the OTCQB Venture Market in Q3 2025, enhancing visibility for U.S. investors.

Financial Strength to Drive Colosseum Forward

Dateline’s cash reserves stand at $1.95 million, bolstered by $1.1 million raised from recent warrant exercises. An additional $350,000 is expected from the partial payment of the sale of the non-core Udu Copper Project in Fiji, bringing the total cash balance to approximately $2.3 million. These funds fully cover the costs of the Colosseum Gold Project’s BFS, ensuring the Company can advance this critical study without delay. The Company has also seen growing interest from warrant holders seeking to convert their holdings, signaling potential for additional organic funding. By monetizing non-core assets like the Udu Copper Project, Dateline is strategically focusing resources on its high-potential U.S. projects, particularly Colosseum.

“We are in a strong financial position to complete the Colosseum BFS, a pivotal step toward realizing the project’s full potential,” said Stephen Baghdadi, Managing Director. “With the support of our shareholders and disciplined capital management, we are well-equipped to deliver value for our investors.”

Colosseum Gold Project: BFS Progress

The BFS for the Colosseum Gold Project, which hosts a JORC-2012 compliant Mineral Resource of 1.1 million ounces of gold (27.1Mt @ 1.26g/t Au), commenced last month and remains on schedule. Key activities include metallurgical test work, with drill core shipped to Kappes, Cassiday & Associates in Nevada for analysis. Australian Mine Design & Development (AMDAD) is overseeing mine engineering, ensuring a comprehensive study that will guide the project’s development. The BFS is expected to be completed in December 2025

Rare Earth Elements: Expanding Colosseum’s Potential

In addition to its gold resources, Colosseum holds significant REE potential. Planning for a targeted REE drilling program is advancing, with program design led by renowned experts Dr. Anthony Mariano and Tony Mariano. The Company is finalizing drill targets and logistics and will soon commence the tender process for a drilling contractor. This program, announced on May 5, 2025, underscores Dateline’s commitment to maximizing the value of Colosseum’s diverse mineral assets.

OTCQB Uplisting to Broaden U.S. Investor Access

Dateline is on track to uplist to the OTCQB Venture Market in Q3 2025, a move designed to increase visibility and accessibility for U.S. investors. This uplisting will complement the Company’s ASX listing and support its growth strategy in the U.S. market, where Colosseum is strategically located in the Walker Lane Trend, less than 10km from the Mountain Rare Earth mine.

About Dateline Resources Limited

Dateline Resources Limited (OTC: DTREF, ASX: DTR) is an Australian publicly listed company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in San Bernardino County, California, which hosts a 1.1 million ounce gold resource and significant REE potential.

For more information, visit www.datelineresources.com.au or follow us on X at https://twitter.com/Dateline_DTR.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or future performance and include, but are not limited to, statements regarding the potential of the Colosseum Project, the expected benefits of the OTCQB listing, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on the company’s current expectations, estimates, and projections, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: fluctuations in the prices of gold and rare earth elements; changes in regulatory requirements or permitting processes; geological or technical challenges in exploration and development; market conditions affecting the company’s ability to raise capital; environmental or social factors impacting operations; risks associated with the OTCQB listing process or trading on a new market; environmental and permitting risks associated with operating in a national preserve; uncertainty regarding the delineation of a mineable rare earth elements resource; risks related to the company’s ability to secure necessary funding for project development; and potential changes in government policies or priorities affecting the critical minerals sector. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Competent Person Statement

The exploration information in this press release has been reviewed by Mr. Greg Hall, a Chartered Professional of the Australasian Institute of Mining and Metallurgy. Mr. Hall has sufficient experience relevant to the style of mineralization and deposit type to qualify as a Competent Person under the JORC Code. He consents to the inclusion of this information in the context in which it appears.

Contact Information:

Stephen Baghdadi
Managing Director
+61 2 9375 2353
info@datelineresources.com.au

Andrew Rowell
White Noise Communications
+61 400 466 226
andrew@whitenoisecomms.com

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

Cost Reductions and Balance Sheet Improvements

Result in Improved Bottom Line and Income from Operations

HOUSTON, TEXAS / ACCESS Newswire / May 19, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with oil and gas properties in the Permian Basin. Today, the Company reports revenue and earnings for the first quarter of 2025.

The management and field teams have made huge strides to upgrade the operational condition of the field; stabilize production rates which had declined by the time the Company closed on the acquisition of LH Operating, LLC (the “Acquisition”); and resolve Acquisition related issues. The Company believes it is now in a position for growth with a bright future ahead.

Key actions since the Acquisition that position the Company for a profitable future:

• The Company entered into an agreement (the “Seller Agreement”) with Pogo Royalty, LLC (“Seller”) that when closed will result in the (i) restructure of the Company’s balance sheet eliminating approximately $40 million in debt and obligations, and (ii) the purchase of a 10% Overriding Royalty Interest in all of the Company’s oil and gas properties. The closing with the Seller is expected to occur in June 2025. Consideration to Seller is agreed to be $22 million in cash and the issuance of 3 million shares of the Company’s Class A common stock. The summary of the Agreement with Seller can be found in the Seller Agreement Press Release published on the Company’s website.

• EON signed an expanded non-binding Letter of Intent (“LOI”) with Enstream Capital Management, LLC (“Enstream”) concerning a volumetric funding arrangement (“VMA”) and revenue sharing for $52.8 million. The funds will be used for the consideration to Seller under the Seller Agreement, field development, and retirement of senior debt. A summary of the Enstream LOI Press Release appears on the Company’s website. We expect to close on this transaction in June 2025.

• As announced in its Horizontal Drilling Program Press Release, the Company conducted a study for horizontal drilling in the lower intervals of the San Andres formation on the Company’s oil and gas properties which could potentially yield up to 20 million untapped barrels of oil. The study has identified 50 well locations to be drilled over several years commencing in Q1 of 2026. Each well will cost approximately $3.7 million to drill and is expected to produce 300 to 400 barrels of oil per day (“BOPD”). The Company is actively in discussions with potential drilling partners to share in the working interest ownership, costs and the related revenues.

• The focus on the field over the past year has resulted in infrastructure enhancements nearing completion and stabilizing production. The Company’s engineers have been using technology and science to analyze well logs and prior results in efforts at increasing production and identification of the best pay in the Seven Rivers formation. The Company’s team has also rolled out the use of an AI application for our well pumpers to improve efficiencies and increase production as described in the AI Implementation Press Release located on the Company’s website.

• The Company continues to make improvements to its balance sheet. In addition to the Seller Agreement, the efforts have included (i) reduction of the senior debt from an original $28 million to approximately $22 million in the principal balance with an escrow reserve of $2.6 million; (ii) termination of a Forward Purchase Agreement (“FPA”) in Q4 of 2024 and removal of related obligations from the balance sheet as of the end of 2024; and (iii) conversion of short-term private loans and warrant liabilities to long-term Convertible Notes (into Class A Common Stock of the Company).

Financial highlights for the quarter ended March 31, 2025:

• Revenues:

  • Total revenues for the quarter were $4.6 million. Up $850K from Q4 of 2024 comprised of: $225K due to higher oil prices in Q1; lower negative non-cash hedging impact in Q1 versus Q4 of $575K; and $50K increase in generated gas revenues.

  • Our current oil production is 70% hedged at a price of $70.00 per barrel or greater through the end of CY 2025.

  • The gas revenues increase was due to the higher market price for gas in Q1 than Q4.

• Field results:

  • The Company had income from operations of $1.8 million for the first quarter.

  • The lease operating expenses (“LOE”) dropped to $683K per month for the first quarter from the $700K per month runrate for most of 2024.

  • The capital expenditures for the first quarter were $600K.

• General and administrative (“G&A”) costs:

  • Salaries and fees decreased in Q1 by $225K, and should remain lower for 2025.

  • While lower than Q4 and Q3 of 2024, the Q1 professional fees for legal, audit and consulting services primarily reflect year end reporting and closing efforts, and certain costs stemming from various trailing legal matters.

  • Insurance costs are down $75K in Q1 due to lower renewal rates for 2025.

• Other income and expense:

  • Interest expense of $1.7 million in Q1 of 2025 is $165K lower than Q4 of 2024 due to note conversions in our efforts to clean-up the balance sheet, and the reduction of the principal balance of the Company’s senior reserve-based loan.

  • The net $500K of non-cash impacts primarily include $300K for the amortization of financing costs, and non-cash impacts on certain liabilities driven by stock prices.

“EON is continuing to take action to reduce costs amid a challenging operating environment. EON’s actions to improve its operating costs structure through transformation producing oil plans are expected to aid our reaching profitability in 2025,” said Dante Caravaggio, President and CEO. “The team has made tremendous progress in upgrading our infrastructure and modernizing the field that has been restricting production. We continue to see the potential of the Seven Rivers waterflood as the field team has commenced the fracing of several wells with good results, and we have re-started acid treatments with an improved formula, which shows promising results. We see as much, or more, potential from horizontal drilling in the San Andres, which we expect to commence in Q1 of 2026. The permitting of such wells and sourcing of a horizontal drilling partner for the San Andres development is underway now.”

“Behind the scenes, we had a team using technology and science to analyze well logs and prior results to assist in increasing production and identifying the best pay in the Seven Rivers. This team also produced a study for a horizontal drilling program in the San Andres interval, which has significant potential for 2026 and beyond,” said Jesse Allen, Vice President of Operations. “Our infrastructure improvements to date are resulting in lower LOE costs in the first quarter, and our analytical work is expected to lower the cost of workovers.”

“As we announced in our press releases dated February 11, 2025, and March 25, 2025, we are renegotiating our debt structure to reduce interest expense and streamline our corporate cost structure which will have a positive impact on profitability in 2025 and beyond,” said Mitchell B. Trotter, CFO. “The management team has made good progress and continues to focus on actions to improve and make the balance sheet stronger.”

About the Oil Field Property

In November 2023, the Company acquired LH Operating, LLC (“LHO”) including its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.

Leasehold rights of LHO, now a wholly owned subsidiary of the Company, include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2023 reserve report from our third-party engineer, William H. Cobb and Associates, Inc. (“Cobb”), reflects LHO to have proven reserves of approximately 15.4 million barrels of oil and 3.5 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956,000,000 barrels of oil.

Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations. With proven oil reserves of over 15 million barrels, combined with the potential 34 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement, and other exploitation efforts on its oil and natural gas properties.

EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American: EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American: EONR WS). For more information on EON, please visit the Company’s website: https://eon-r.com/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built across several commercial-stage medical device and pharmaceutical companies including Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical, as well as technical accounting and auditing experience at PricewaterhouseCoopers LLP.

“Jennifer brings a wealth of commercial experience to the CFO role, which we believe will be instrumental as we transition from a development-stage company to a commercial entity,” said Robert Berman, enVVeno Medical’s Chief Executive Officer. “In addition to overseeing our financial strategy and operations, Jennifer will play a critical role in strengthening our financial infrastructure, supporting our commercialization efforts for VenoValve, and expanding our relationships with institutional investors and analysts. Her experience navigating growth and change will be a valuable asset as we enter this next phase of the Company’s evolution.”

Ms. Bright is a Certified Public Accountant and received a B.A. degree in Business Administration, Accounting, from the University of Washington. She succeeds Craig Glynn, who will continue to be available to the Company in an advisory capacity.

The Company is currently developing two devices for the treatment of deep venous CVI, a potential first-in-class surgical replacement venous valve called the VenoValve®, and a non-surgical replacement venous valve called enVVe®. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for replacement venous valves, including approximately 1.5 million with active venous ulcers. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. In the third quarter of 2025, the Company expects to file an Investigational Device Exemption (IDE) seeking authorization from the FDA to begin enVVe pivotal trial.

About CVI
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company’s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous CVI. The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025 and is currently performing the final testing necessary to seek approval from the FDA for the enVVe pivotal trial.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

###

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

YUMA, AZ / ACCESS Newswire / May 19, 2025 / Onvida Health, a leading provider of integrated care throughout Arizona, and Ambience Healthcare, the leading AI platform for clinical documentation, CDI, and coding, today announced the launch of a pilot program across multiple clinical sites.

Onvida Health clinicians across outpatient, inpatient, and emergency department settings will be piloting Ambience’s suite of AI applications to generate comprehensive and compliant documentation in real time-directly within Epic’s Electronic Health Record (EHR).

The pilot, launching in June 2025, reflects Onvida Health’s ongoing commitment to delivering the highest quality care in the region-while supporting clinicians with innovative technology to improve efficiency, reduce burnout, and increase time with patients.

With this technology, Onvida Health providers will spend less time on administrative work and more time with patients-while strengthening documentation integrity, supporting compliance, and improving financial accuracy.

“We are investing in the most advanced AI platform in healthcare because we believe the best patient care starts with supporting our clinicians,” said Marc Chasin, M.D., Senior Vice President and Chief Information Officer at Onvida Health. “Ambience will allow our clinicians to spend less time on paperwork and more time with their patients-while improving quality, accuracy and compliance.”

Ambience’s suite of AI applications includes:

• Scribing: The only AI medical scribe built to support the medicine, workflows, and coding and billing requirements of more than 100 specialties and subspecialties, including inpatient and emergency medicine

• CDI: A point-of-care CDI assistant that analyzes conversations and surfaces precise ICD-10 codes, CPT codes, and full audit trails for revenue cycle teams

• Patient Summaries: Comprehensive summaries for patients, their families, and caretakers

• Referrals: Clinically relevant and well-organized referral letters for primary care clinicians and specialists

Ambience’s AI platform helps clinicians design their agenda before a patient visit begins. Once the clinician is in the room with a patient, Ambience listens to the conversation. The technology then leverages all of the patient’s historical EHR data, as well as the recording of the visit, to automate documentation for the patient and clinician. This includes clinical notes, after-visit summaries, referral letters, and CPT and ICD-10 coding suggestions.

“By equipping our clinicians with Ambience’s AI technology, we’re ensuring that every patient receives more personalized attention, more thorough care, and a better overall experience,” said Kristina Diaz, M.D., President of Onvida Health Medical Group. “This partnership is about giving our patients and clinicians the time, focus, and quality they deserve-putting the human connection back at the center of every visit.”

Clinicians at leading health systems across North America leverage Ambience before, during, and after patient encounters. Ambience has been deployed at Cleveland Clinic, UCSF Health, St. Luke’s Health System, Houston Methodist, John Muir Health, Memorial Hermann Health System, and others.

“We are honored to partner with Onvida Health, an organization deeply committed to putting patients first, supporting their providers, and driving innovation,” said Mike Ng, CEO and Co-Founder of Ambience Healthcare. “Today, clinicians spend only about a quarter of their time on direct patient care – and together with Onvida Health, we are going to change that. By supporting every clinical encounter with Ambience’s AI technology, we’re helping clinicians reclaim their time, enhance compliance and accuracy, and refocus healthcare around what matters most: the patient.”

About Onvida Health

Onvida Health is a not-for-profit hospital system with 430 inpatient beds, 45 outpatient clinics and a free-standing Emergency Department. The Onvida Health team includes 495 providers representing 52 specialties, 4000 employees and hundreds of volunteers who work closely together to create a welcoming, caring and compassionate environment for patients and their families. Onvida Health is dedicated to building a healthier tomorrow for Yuma County residents and the surrounding southwestern Arizona communities.

About Ambience Healthcare
Ambience Healthcare’s mission is to supercharge healthcare providers with breakthrough generative AI technology. Ambience’s products are currently leveraged by leading provider organizations and health systems across North America to reduce documentation burden, alleviate provider burnout, and improve care quality. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco, California, and backed by Andreessen Horowitz, OpenAI Startup Fund, Human Capital, Kleiner Perkins, Martin Ventures, AIX Ventures, AirTree Ventures, John Doerr, Jeff Dean, Richard Socher, Pieter Abbeel, Anne Wojcicki, Eren Bali, Jay Desai, Nish Bhat, Matt Mochary, and others. To learn more, visit ambiencehealthcare.com.

For more information, press only:

Karina Stabile
Aria Marketing for Ambience Healthcare
kstabile@ariamarketing.com
516-317-5835

Jenn Lotz Williams
(504) 376-3253
Jwilliams4@onvidahealth.org

SOURCE: Ambience

View the original press release on ACCESS Newswire